CoviCept Therapeutics, LLC (represented by Forbion)
Covicept Therapeutics is a San Diego based company developing an oral small molecule drug that inhibits the replication of SARS-CoV-2 and other RNA viruses including Dengue, Chikungunya and Zika. The drug is currently tested in the Brazil Phase 2 HALOS trial (2021). Forbion’s .
DayOne is a full service digital health innovation platform which is reimagining the future of health by building and growing digital health and med tech ventures in Basel, Switzerland. We are Switzerland's leading digital health accelerator, dedicated to launching and scaling digital health ventures in Europe.
To date DayOne has accelerated 20 exciting digital health ventures which now employ 131 people and are valued at over 65 million CHF. We have recently raised over 3 million CHF in funds to increase our offering and accelerate more digital health and med tech ventures over the next 3 years. If you are an investor looking for a unique opportunity or a portfolio manager looking for ways to accelerate you health ventures in a top 3 biopharma location, then please be in touch.
docdok.health is an internationally multi-awarded Swiss/Israeli digital health startup delivering personalized healthcare. More than 90 % of available patient data are not used in the current healthcare system. This has to change. We deliver the solution.
To create a world of bionic vision for those who have lost their sight.
To provide best in class bionic vision restoration systems enabling the blind to regain greater autonomy and improved quality of daily living.
Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy.
Prima System features a miniaturized and totally wireless sub-retinal PRIMA implant, a pocket computer equipped with breakthrough algorithms, and a pair of glasses which captures the visual scene.
For the novel breakthrough Prima system, the exclusive transfer of the patented technology was granted by Stanford’s University to Pixium Vision to develop and industrialize the PRIMA bionic vision system.
Pixium Vision is currently conducting in France and in the United States, two feasibility clinical trials with PRIMA, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD), for which there is no treatment available to date.
Sequana Medical is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a frequent complication of many large diseases including advanced liver disease driven by NASH-related cirrhosis and heart failure, with diuretic resistance being widespread.
The alfapump is a unique, fully implanted wireless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally eliminated through urination. DSR is Sequana Medical’s proprietary approach to managing sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity.
The alfapump has been granted breakthrough device designation by the U.S. FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing POSEIDON study showed positive outcomes against all primary endpoints and a rapid and persistent clinically important improvement in quality of life. This study is intended to support a future marketing application of the alfapump in the U.S. and Canada. In Europe, the alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and over 850 alfapump systems have been implanted to date.
Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure. RED DESERT, the repeated dose alfapump DSR study in diuretic-resistant heart failure patients has demonstrated that repeated DSR therapy is able to both manage the fluid and sodium balance of these patients as well as restore their diuretic response and improve their cardio-renal status. The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.
Alertgy is a pioneer in 100% non-invasive continuous blood glucose monitoring technology. Through the use of its patented radio frequency sensor Alertgy’s DeepGluco wearable device is able to accurately measure blood glucose in real time, up to 3 times per minute. Most importantly, using our proprietary AI algorithm, DeepGluco can provide invaluable, up to the minute life-saving alerts to the users and their designated HCPs. Unlike other CGMs, we eliminate interstitial lag as well as painful and uncomfortable side effects of patches, needles, and implants. The final DeepGluco form factor will be similar to modern smart watches, available to consumers following FDA approval.
Aleva Neurotherapeutics develops the next generation of directional Deep Brain Stimulation (DBS) systems based on MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. The first application is in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor. Aleva was founded in 2008 as a spin-off of the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland. It has raised 62 M to date from european VCs, family offices and private investors.
Pulsify Medical develops wearable, flexible and smart ultrasound patches for non-invasive, real time monitoring of critical cardiac physiological parameters, in particular cardiac output.
A spin off from the renowned institutions imec and the University Leuven (both based in Leuven, Belgium), Pulsify is building on unique and protected IP to develop the world's first ultrasound patch that can be industrialised at scale.
The Pulsify cardiac patch is roughly 10x10cm in size and will be attached to the chest of a patient to monitor 24/7 the performance of the heart, in particular the so-called Cardiac Output, and related physiological parameters such as Ejection Fraction and Stroke Volume.
Who will benefit? Patients with for example heart failure, coronary artery disease, structural heart disease, cardiac rhythm management, congenital heart disease, peripheral heart disease, ischemic heart disease, history of myocardial infarction substance/drug abuse, shock, cytotoxicity. These are patients in the hospital ICU's, in the hospital wards and at home.
The benefits include better health outcomes, ease of use (especially in the home environment) and peace of mind, knowing that the patch will warn both patient and physician if the cardiac performance is becoming dangerous.
Currently no appropriate solutions exist in the market: invasive catheters have intrinsic drawbacks (infection/complication risk; inaccuracy; ICU use only), whereas handheld ultrasound probes cannot monitor cardiac performance beyond a spot-measurement. Pulsify Medical’s smart patch will be the only solution able to monitor cardiac output non-invasively, for the long-term, safe, and at lower cost. They will be easy to apply and comfortable for the patient. Pulsify Medical’s patch is thereby truly differentiated from competition.
Sense Neuro Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes—ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage. Learn about the ongoing pivotal trial for continuous monitoring of intracranial hemorrhage, and the recent military contract to accelerate development of a field device on our website or find Sense Neuro Diagnostics on LinkedIn or Twitter @SenseDx.
Spindiag provides a rapid molecular point-of-care test. On our syndromic testing platform, we commercialized a SARS-CoV-2 test and are expanding the test menu towards a respiratory infections panel and detection of multi-drug resistant bacteria in 2022. Currently, Spindiag has an installed base of 150 systems in German hospitals and a cumulative turnover of > 5 M€ in 2021 so far. Spindiag's unique profile of a fast (40-50 minutes), very easy to use (just insert the patient swab sample) and broad (up to 36 parameters per patient sample tested) diagnostic solution makes it an attractive choice for hospitals and strategic investors.
Healiva is a Swiss startup venture located in Lugano developing products for acute to chronic wounds.
We are a patient centric Biotech company, delivering precision medicine by offering a range of products in various application formats for treating acute to chronic wounds. It uses a multi-pronged approach to address patient needs by combining, enzyme technology, medical devices and cell therapy to deliver personalized solutions from bench-to-bedside. To provide patients and healthcare professionals with advanced products and therapies for the wound management by leveraging on best in class innovations.
AiiNTENSE develops a clinical and innovation platform in Neurosciences with - Business and telemedicine applications for personalised patient care and hospital efficiency. - Data warehouses specialised in Neuroscience for greater efficiency and enhancement of medical research projects - Cognitive assistants from data lakes that will augment clinical applications Data quality, an interoperable and secure platform, and ethical governance are the foundation of an ecosystem of public and private partners.
Ancora.ai is a patient-first technology company that is revolutionizing research. The company’s mission is to improve healthcare for all by accelerating innovation in medicine. Ancora.ai’s core product is an AI-powered platform that seamlessly connects patients and physicians to clinical research. Using Ancora.ai, anyone can identify their set of relevant clinical trials in 5 min. Ancora.ai works directly with patients, with hospitals, and with a diverse set of other stakeholders in healthcare (E.g., genetic testing providers) to connect patients to research.
Aortyx is a Medtech company dedicated to change the established paradigm of temporary repair to definitive restoration in the aortic diseases field. Unlike our competitors, we develop solutions that focus on imitating the biomechanical properties of the damaged tissue to allow them to smoothly integrate in the damaged tissue. We do so with the most advanced technology, focusing on the true needs of aortic disease patients and of cardiovascular surgeons, our most relevant stakeholders. Aortyx will deliver a revolution to this market, as we see our products being rapidly adopted to become the market leader and a reference for others.
Biome Diagnostics GmbH (BiomeDx®) is an Austrian based MedTech company committed to advance precision medicine by pioneering microbiome-based technologies that transforms cancer care.
The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice.
BiomeDx is worldwide the first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.
FIRALIS is a biotechnology company located in the very heart of BioValley, on the true triple border of FR-DE-CH, only a few minutes walking distance to Basel, the pharmaceutical capital of Europe.
Firalis creates novel values via biomarker discovery, development and regulatory qualification and brings to market biomarker-based diagnostic products. With a comprehensive expertise in the field, Firalis develops diagnostic kits and provides an extensive range of biomarker services; to improve therapeutic decisions as well as disease outcomes and patient comfort, finally to reduce healthcare costs at remarkable extents.
Grapheal is a young MedTech company based in Grenoble (France) that addresses unmet needs in medical diagnostics. Its mission is to create a new generation of biosensors for real-time and affordable diagnostics by merging digital biosensing with wireless near-field communication. This new class of wirelessly connected biosensors opens the door to many new applications relying on instant and direct detection of biomolecules without molecular amplification. It supports accurate and informed decisions in a decentralized healthcare system by empowering caregivers, professionals, and everyday users. These new embedded biosensing systems are made for fast on-site diagnosis or real-time remote patient monitoring. It features biocompatible graphene-based nanomaterials, flexible embedded electronics, software data analysis, and medical cloud technologies.
During the last six months, Grapheal has finalized two products that address different markets: a new generation digital COVID-19 test directly coupled to a digital pass (TestNPass) and a wound care digital assistant (WoundLAB) to improve the monitoring of hard-to-heal wounds.
WoundLAB is a flexible and transparent graphene-based biosensor patch that continuously records and stores wound biochemical parameters. A smartphone app communicates these data to a telemedicine cloud for data aggregation and analysis. This solution allows caregivers to monitor wound healing remotely, prompting alerts if any infections or medical complications arise.
TestNPass is Grapheal’s ultra-rapid digital Covid test that is easy to implement anywhere for high-flow screening. Within 5 minutes, the digital test detects the presence of the virus without the requirement of dedicated reading equipment other than a smartphone or a standard NFC-connected device. The test result is tamper-proof and encrypted into an NFC tag to constitute a standalone biometric access control pass.
MJN Neuroserveis S.L. was founded in 2014 with the mission of improving the quality of life of epilepsy-affected people. Our solution, MJN-SERAS, is the first wearable device that can alert patients before seizures occurs by the continuous monitoring of brain signals.
Over 250 million people in Europe and the United states suffer from chronic constipation due to slow intestinal transit - mainly patients with chronic neurological diseases (SCI, MS, PD, etc.) and the elderly- generating an annual cost of 100 billion € to the healthcare systems.
USMIMA S.L. has developed MOWOOT, the first non-pharmacological, non-invasive solution to chronic constipation.
The MOWOOT device consists of a desktop unit and a wearable belt: the desktop controls, personalizes and administers the treatmentin in real-time and the wearable belt produces a wave-like exo-peristaltic effect that emulates natural colonic movement patterns to promote intestinal secretion and intestinal transit, using a patented novel pneumatic technology.
MOWOOT is CE certified (medical device class IIa), clinically proven, IP protected and on the market, with first sales and distribution partners in Germany, UK, Netherlands and Spain.
RDS develops a high-fidelity remote monitoring solution for vital parameters, comfortable to wear, which facilitates and secures early discharge of patients from the hospital. It improves patients management, reduces complications for the patient and costs for the hospital.